Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case

We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibitor of PDGFRA and KIT mutations. Based on NAVIGATO...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Daria A. Filonenko, Bela M. Medvedeva, Andrey A. Meshcheryakov
Formato: article
Lenguaje:RU
Publicado: IP Habib O.N. 2021
Materias:
Acceso en línea:https://doaj.org/article/6e46ed6345224af8a1b117b56a28b0d7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares